Circadian Genes and Risk for Prostate Cancer
Abstract
We propose that genetic susceptibility to prostate cancer may be in part due to variations in the core circadian genes that regulate circadian rhythms and that serum sex steroid hormone levels modify the effect of circadian gene polymorphisms on prostate cancer risk. Our study is nested within the Prostate Cancer Prevention Trial (PCPT), a randomized placebo-controlled clinical trial to determine if finasteride (an inhibitor of androgen bioactivation) could prevent prostate cancer. In Year 3 of the award, we completed genotyping at the University of Texas Health Science Center at San Antonio (UTHSCSA) genotyping facility We have also worked with the PCPT Statistical Center to ensure that the genotyping assays for our study is of good quality. A subset of the data was presented at the DoD PCRP IMPaCT Meeting in Orlando, FL in March 2011. We have also been involved in analyzing and manuscript preparation on the serum androgen data, a separate study whose results will help guide analysis for Aim 2 of our study. Data analysis and manuscript preparation is underway and will be completed in the nocost extension year of the grant.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2011
- Accession Number
- ADA577825
Entities
People
- Ann Hsing